All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
China saw $28.5 billion invested in its life sciences sector in 2020, which was double the previous year’s amount and sets a five-year high. Partnering activities and IPOs also grew exponentially over the last five years to set records. “After a somewhat down year in 2019 in terms of investment activity in China’s life sciences, 2020 is completely back on track. Venture capital investment, partnering activity and IPOs are literally exploding,” said Greg Scott, founder and chairman of Chinabio Group, at the Chinabio Partnering Forum that opened May 10.
Read More
Shenzhen Pregene Biopharma Co. Ltd. has outlicensed its internally developed anti-BCMA CAR T-cell therapy candidate, PRG-1801, to Indian pharma giant Dr. Reddy's Laboratories Ltd. in a $162.5 million deal to develop and commercialize it in India. The candidate, which is being developed by Pregene to treat relapsed/refractory multiple myeloma, is now in a phase I trial in China after anIND approval in March 2020.
HONG KONG – The Biden administration’s support for a TRIPS waiver of COVID-19 vaccine patents has already met a chorus of resistance from Western companies. In Asia, skepticism about how it would be achieved and what it will cover, is widespread. Read More
Beigene Ltd.’s PARP inhibitor, pamiparib, won conditional approval from China’s National Medical Products Administration for treating patients with germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. Read More
HONG KONG – Olix Pharmaceuticals Inc. has entered an extensive research collaboration to test its RNAi therapeutic, OLX-104C, with Fimanac, PCI Biotech Holding ASA’s delivery technology for nucleic acid-based therapies, with the aim of reducing off-target effects while treating androgenic alopecia, or hair loss. Read More
The 2021 Special 301 Report recently released by the U.S. Trade Representative is mostly déjà vu for the 32 countries included on the Priority Watch and Watch Lists, as all of them have appeared before on the lists that call out U.S. trading partners for unfair IP practices that disadvantage foreign companies. Read More
The Biden administration’s May 5 about-face on the proposed TRIPS waiver of intellectual property (IP) protections for COVID-19-related medical products is not playing well with U.S. industry, EU trading partners and others concerned about the long-term unintended consequences. Read More
Once again, the World Trade Organization postponed a decision on a temporary IP waiver for COVID-19 vaccines and other related medical products. Read More
PERTH, Australia – Imagion Biosystems Ltd. has entered a collaborative research program with Patrys Ltd. to combine their technologies to target brain tumor imaging and diagnosis. Read More
Since joining the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use in 2017, China has approved clinical trials and marketing of drugs a lot faster with simultaneous clinical development at home and abroad. Read More
Biopharmas in Asia-Pacific raising money in public or private financings, including: Alebund, Cocrystal, Resverlogix, Shenzhen Hepalink, Summit Healthcare Acquisition, Valneva. Read More
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ampio, Astellas, Beigene, Biontech, Clarity, Eagle, Eli Lilly, Everest Medicines, GC, Glaxosmithkline, Hutchmed, Kyowa Kirin, Pfizer, RDIF, R-Pharm Germany, Vir. Read More
